Alnylam Pharmaceuticals, Inc. vs Applovin Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Applovin Corporation trades at $321 (market cap $106.65B). The key difference: Applovin Corporation is far larger — about 3.6× Alnylam Pharmaceuticals, Inc.'s market cap. Which is the better fit depends on your goals.
| ALNY | APP | |
|---|---|---|
Market Cap | $29.60B | $106.65B |
Sector | Health | Technology |
52-Week High | $491.22 | $733.60 |
52-Week Low | $205.48 | $318.68 |
Enterprise Value | $27.56B | $107.11B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
AppLovin (APP) trades at $346.80, down 3.32% amid a bearish technical outlook despite strong fundamentals. The stock faces selling pressure after Q2 revenue missed expectations, though it maintains exceptional profitability with 64.58% net margins and 53% YoY revenue growth. Analyst consensus remains bullish with an $569.60 price target, but technical indicators show 18 sell signals versus 2 buys.
The stock presents a growth-at-a-reasonable-price opportunity post-selloff, trading at 26x P/E with 80% analyst buy ratings. Key risks include execution volatility in AI-driven ad pricing and high valuation multiples. Upside depends on Q3 results meeting elevated guidance of 47% growth.
Trailing returns across standard periods
Latest headlines on both assets
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →AppLovin provides a software platform for mobile app developers to market, monetize, and analyze their apps. Its AI-powered tools help developers grow their business by connecting them with global advertising networks.
Read more on APP →